Bristol Myers Squibb Company (NYSE:BMY) Shares Sold by Private Trust Co. NA

Private Trust Co. NA reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 4.5% in the 1st quarter, Holdings Channel reports. The firm owned 31,829 shares of the biopharmaceutical company’s stock after selling 1,514 shares during the period. Private Trust Co. NA’s holdings in Bristol Myers Squibb were worth $1,941,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in BMY. Pinney & Scofield Inc. purchased a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $26,000. Fairway Wealth LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter valued at $28,000. Transce3nd LLC acquired a new stake in Bristol Myers Squibb during the 4th quarter worth $28,000. Finally, Global Wealth Strategies & Associates grew its position in Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 275 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $47.64 on Thursday. Bristol Myers Squibb Company has a 12-month low of $39.35 and a 12-month high of $63.33. The firm has a market cap of $96.95 billion, a price-to-earnings ratio of 17.84, a price-to-earnings-growth ratio of 1.41 and a beta of 0.36. The company’s 50-day moving average is $47.78 and its two-hundred day moving average is $53.75. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($4.40) earnings per share. Research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.21%. Bristol Myers Squibb’s payout ratio is currently 92.88%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction on Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president directly owned 83,513 shares of the company’s stock, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on BMY. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Piper Sandler assumed coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price objective for the company. William Blair reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Jefferies Financial Group dropped their target price on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a report on Wednesday, April 23rd. Finally, UBS Group decreased their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $58.00.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.